A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AbbVie (prior sponsor, Abbott)
To assess the safety, tolerability and pharmacokinetics of ABT-494 in healthy volunteers and in patients with rheumatoid arthritis.
Age
18–75
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Healthy Volunteers:
Male and female subjects 18 to 55 years of age, inclusive.
Subject is judged to be in good general health.
Rheumatoid Arthritis Patients:
Male and female patients 18 to 75 years of age, inclusive.
Subject has a diagnosis of rheumatoid arthritis for at least six months.
Subject has been on methotrexate therapy for at least three months and on a stable dose for at least four weeks.
You may not be if
History or evidence of active or latent tuberculosis.
History or significant allergic reaction to any drug.
Use of known strong CYP3A and CYP2D6 inhibitors and CYP3A inducers within 21 days or within 5 half-lives of the respective medication, whichever is longer.
Current or expected need for oral intake of at least 10 mg prednisone per day or equivalent corticosteroid therapy.
History of acute inflammatory joint disease of different origin other than rheumatoid arthritis (rheumatoid arthritis patients).
Clareo Health | A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494
